The contract manufacturing market for Pharmaceuticals in China is projected to grow at an annualized rate of ~8.9%, till 2030

Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.

 

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link

 

Key Market Insights

• Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing
• CMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providers
• The current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few years
• Big pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R&D centers and manufacturing facilities focused on pharmaceutical products
• Innovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%
• In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Table of Contents

 

1. PREFACE
   1.1. Scope of the Report
   1.2.                  Research Methodology
   1.3.                  Chapter Outlines
   
   2.                     EXECUTIVE SUMMARY
2. 
   INTRODUCTION
   3.1. Chapter Overview
   3.2.                  Need for Outsourcing in the Pharmaceutical Industry
   3.3.                  Overview of the Pharmaceutical Contract Manufacturing
   3.4.                  Evolution of the Pharmaceutical Contract Manufacturing Industry
   3.4.1.                Traditional Contract Manufacturing Organizations (CMOs)

3.4.2.                Modern CMOs
3.5.                  Services Offered by CMOs
3.6.                  Pharmaceutical Contract Manufacturing Scenario in China

3.7.                  Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

 

1. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
   4.1.                  Chapter Overview
   4.2.                  Small Molecule and Large Molecule Drugs / Therapies
    

4.2.1.                Comparison of General Characteristics
4.2.2.                Comparison of Manufacturing Processes
4.2.3.                Comparison of Key Manufacturing-related Challenges

 

1. MARKET OVERVIEW
   5.1.                   Chapter Overview
   5.2.                   Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

5.2.1.                Analysis by Year of Establishment
5.2.2.                Analysis by Company Size
5.2.3.                Analysis by Location of Headquarters

5.2.4.                Analysis by Type of Product (API and FDF)
5.2.5.                Analysis by Type of FDF
5.2.6.                Analysis by Type of Packaging

5.2.7.                Analysis by Manufacturing Facilities

 

5.3.                   Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies

5.3.1.                Analysis by Year of Establishment

5.3.2.                Analysis by Company Size

5.3.3.                Analysis by Location of Headquarters

5.3.4.                Analysis by Type of Product (API and FDF)

5.3.5.                Analysis by Type of FDF

5.3.6.                Analysis by Type of Packaging

5.3.7                 Analysis by Manufacturing Facilities

 

1. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
   6.1.                   Chapter Overview
   6.2.                   Chinese Pharmaceutical CMOs: List of Manufacturing Facilities
   
   6.2.1.                Analysis by CMO Manufacturing Facilities in Eastern China
   6.2.2.                Analysis by CMO Manufacturing Facilities in Southern China
   6.2.3.                Analysis by CMO Manufacturing Facilities in Northern China
    
2. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA

7.1.                   Chapter Overview

7.1.1.                Health Authorities in China

7.1.2.                Overview of Regulatory Guidelines in China

 

1. COMPANY PROFILES

8.1.                   Chapter Overview

8.2.                   2Y-Chem

8.2.1.                Company Overview

8.2.2.                Service Portfolio

8.2.3.                China-based Manufacturing Facilities and Capabilities

8.2.4.                Recent Developments and Future Outlook

 

8.3.                   Aurisco Pharmaceutical

8.3.1.                Company Overview

8.3.2.                Service Portfolio

8.3.3.                China-based Manufacturing Facilities and Capabilities

8.3.4.                Recent Developments and Future Outlook

 

8.4.                   ChemPartner

8.4.1.                Company Overview

8.4.2.                Service Portfolio

8.4.3.                China-based Manufacturing Facilities and Capabilities

8.4.4.                Recent Developments and Future Outlook

 

8.5.                   Dorrapharma

8.5.1.                Company Overview

8.5.2.                Service Portfolio

8.5.3.                China-based Manufacturing Facilities and Capabilities

8.5.4.                Recent Developments and Future Outlook

 

8.6.                   Hubei Biocause Pharmaceutical

8.6.1.                Company Overview

8.6.2.                Service Portfolio

8.6.3.                China-based Manufacturing Facilities and Capabilities

8.6.4.                Recent Developments and Future Outlook

 

8.7.  &nb